Global Female Sexual Dysfunction Treatment Market 2019-2023
A key factor driving the growth of the market is the increasing
prevalence of chronic diseases. Sexual dysfunctions are common in women
and involve loss of desire, orgasm problems, and pain during sex. The
onset of sexual dysfunctions in women is attributed to hormonal factors,
menstrual irregularities, amenorrhea, lack of vaginal lubrication, and
failure to conceive. Female sexual dysfunctions can be caused due to
various chronic diseases such as diabetes. Patients with diabetes may
have several clinical conditions, including overweight, hypertension,
metabolic syndrome, and atherogenic dyslipidemia, which are risk factors
for sexual dysfunction in women. Therefore, rising prevalence of these
conditions across the globe is expected to increase the patient pool
with a large number of women having sexual dysfunctions, which, in turn,
will drive the growth of the global female sexual dysfunction treatment market during the forecast period.
Global female sexual dysfunction treatment market: Increasing use of drugs causing sexual dysfunctions in women
There are several classes of drugs such as antidepressants, antipsychotics, antiepileptics, and contraceptives, which result in sexual dysfunction in women. Hypertension is associated with sexual dysfunction and is more common in women. Drugs such as beta blockers decrease sexual desire in women. Alpha-adrenergic drugs also reduce sexual desire and arousal in women. Similarly, antidepressants drugs cause sexual difficulties. Furthermore, the majority of sexual dysfunction is caused by dopamine receptor blockade. This causes hyperprolactinemia with subsequent suppression of the hypothalamic-pituitary-gonadal axis and hypogonadism in women resulting in decreased sexual desire, impaired arousal, and orgasm. In addition, drugs used in the treatment of epilepsy, such as gabapentin and topiramate, have been associated with orgasmic dysfunction and reduced libido in women. Thus, the use of such drugs will increase the incidences of sexual dysfunctions in women, thereby increasing the demand for drugs to treat sexual dysfunctions in women.
Global female sexual dysfunction treatment market: Segmentation analysis
This market research report segments the global female sexual dysfunction treatment market by type (non-hormonal therapy and hormonal therapy) and geographical regions (North America, Europe, Asia and ROW).
Global female sexual dysfunction treatment market: Increasing use of drugs causing sexual dysfunctions in women
There are several classes of drugs such as antidepressants, antipsychotics, antiepileptics, and contraceptives, which result in sexual dysfunction in women. Hypertension is associated with sexual dysfunction and is more common in women. Drugs such as beta blockers decrease sexual desire in women. Alpha-adrenergic drugs also reduce sexual desire and arousal in women. Similarly, antidepressants drugs cause sexual difficulties. Furthermore, the majority of sexual dysfunction is caused by dopamine receptor blockade. This causes hyperprolactinemia with subsequent suppression of the hypothalamic-pituitary-gonadal axis and hypogonadism in women resulting in decreased sexual desire, impaired arousal, and orgasm. In addition, drugs used in the treatment of epilepsy, such as gabapentin and topiramate, have been associated with orgasmic dysfunction and reduced libido in women. Thus, the use of such drugs will increase the incidences of sexual dysfunctions in women, thereby increasing the demand for drugs to treat sexual dysfunctions in women.
Global female sexual dysfunction treatment market: Segmentation analysis
This market research report segments the global female sexual dysfunction treatment market by type (non-hormonal therapy and hormonal therapy) and geographical regions (North America, Europe, Asia and ROW).
Comments
Post a Comment